Prospects of a novel vaccination strategy for human gamma-herpesviruses.
Due to the oncogenic potential associated with persistent infection of human gamma-herpesviruses, including Epstein-Barr virus (EBV or HHV-4) and Kaposi's sarcoma-associated herpesvirus (KSHV or HHV-8), vaccine development has focused on subunit vaccines. However, the results using an animal model of mouse infection with a related rodent virus, murine gamma-herpesvirus 68 (MHV-68, γHV-68, or MuHV-4), have shown that the only effective vaccination strategy is based on live attenuated viruses, including viruses engineered to be incapable of establishing persistence. Vaccination with a virus lacking persistence would eliminate many potential complications. Progress in understanding persistent infections of EBV and KSHV raises the possibility of engineering a live attenuated virus without persistence. Therefore, we should keep the option open for developing a live EBV or KSHV vaccine.
Wu
Ting-Ting
TT
Department of Molecular and Medical Pharmacology, School of Medicine, University of California at Los Angeles, CA 90095, USA. twu@mednet.ucla.edu
Blackman
Marcia A
MA
Sun
Ren
R
D000818:Animals; D002471:Cell Transformation, Neoplastic / Q000235:genetics; D002472:Cell Transformation, Viral / Q000235:genetics; D004195:Disease Models, Animal; D018142:Gammaherpesvirinae / Q000472:pathogenicity / Q000502:physiology*; D006566:Herpesviridae Infections / Q000276:immunology* / Q000517:prevention & control / Q000821:virology; D022283:Herpesvirus Vaccines / Q000235:genetics; D006801:Humans; D057131:Immune Evasion; D051379:Mice; D014412:Tumor Virus Infections / Q000276:immunology* / Q000517:prevention & control / Q000821:virology; D014611:Vaccination / Q000639:trends; D014613:Vaccines, Attenuated / Q000235:genetics; D017735:Virus Latency / Q000235:genetics / Q000276:immunology; D014779:Virus Replication
D022283:Herpesvirus Vaccines; D014613:Vaccines, Attenuated